Billy Vuong

Billy Vuong

Auto-generated profile, based on publicly available information

Billy Vuong

College of Pharmacy Rady Faculty of Health Science University of Manitoba Winnipeg MB R3E 0T5 Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in ChemMedChem
Verified
Journal Article
Open access
NSNitesh Sanghai
Nitesh Sanghai
BVBilly Vuong
Billy Vuong
ABAhmet Burak Berk
Ahmet Burak Berk
MAMuhammad Shaharyar K. Afridi
Muhammad Shaharyar K. Afridi
Geoffrey TranmerGeoffrey Tranmer
Geoffrey Tranmer
Neurodegenerative diseases (NDDs) like Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic lateral sclerosis (ALS) possess multifactorial aetiologies. In recent years, our understanding of the biochemical and molecular pathways across NDDs has increased, however, new advances in small molecule–based therapeutic strategies targeting NDDs are obscure and scarce. Moreover, NDDs have been studied for more than five decades, however, there is a paucity of drugs that can treat NDDs. Further, the highly lipoidal blood–brain barrier (BBB) limits the uptake of many therapeutic molecules into the brain and is a complicating factor in the development of new agents to treat neurodegeneration. Considering the highly complex nature of NDDs, the association of multiple risk factors, and the challenges to overcome the BBB junction, medicinal chemists have developed small organic molecule–based novel approaches to target NDDs over the last few decades, such as designing lipophilic molecules and applying prodrug strategies. Attempts have been made to utilize a multitarget approach to modulate different biochemical molecular pathways involved in NDDs, in addition to, medicinal chemists making better decisions in identifying optimized drug candidates for the central nervous system (CNS) by using web–based computational tools. To increase the clinical success of these drug candidates, an in vitro assay modeling the BBB has been utilized by medicinal chemists in the pre–clinical phase as a further screening measure of small organic molecules. Herein, we examine some of the intriguing strategies taken by medicinal chemists to design small organic molecules to combat NDDs, with the intention of increasing our awareness of neurodegenerative therapeutics.
1

27 October 2026 in ChemMedChem
Verified
Journal Article
Open access
PDF file
NSNitesh Sanghai
Nitesh Sanghai
BVBilly Vuong
Billy Vuong
MAMuhammad Shaharyar K. Afridi
Muhammad Shaharyar K. Afridi
SLSasha Elise Leggett
Sasha Elise Leggett
HRHemin Roghzai
Hemin Roghzai
Geoffrey TranmerGeoffrey Tranmer
Geoffrey Tranmer
Background: Boron (B), a group 13 metalloid, has emerged as a versatile element at the intersection of chemistry, biology, and medicine. Its electron‐deficient nature and ability to reversibly interconvert between trigonal planar ( sp 2 ) and tetrahedral ( sp 3 ) geometries enable dynamic covalent interactions with biological nucleophiles, making boron‐containing compounds (BCCs) attractive pharmacophores that selectively interact with reactive oxygen species (ROS) and are ROS‐responsive for therapeutic development. BCCs possess antioxidant, anti‐inflammatory, and metal‐chelating properties that make them attractive candidates for neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS), a fatal and multifactorial motor neurodegenerative disorder, is characterized by oxidative stress, neuroinflammation, mitochondrial dysfunction, and metal dyshomeostasis, providing a strong rationale for exploring boron‐based therapeutics. Methods: This review examines current literature on B chemistry, pharmacology, and translational applications, with emphasis on mechanisms relevant to ALS pathogenesis. This review focuses on ROS‐responsive B scaffolds, blood–brain barrier (BBB) permeability, neuroprotective mechanisms, hormonal modulation, metal chelation, and emerging preclinical evidence supporting boron‐based interventions. Conclusions: BCCs represent a promising yet underexplored therapeutic platform for ALS and related neurodegenerative disorders. Their ROS‐responsive, redox‐modulating, and neuroprotective properties, combined with favorable CNS drug‐like pharmacokinetics, offer a mechanistically distinct approach to disease modification. Emerging preclinical evidence strongly supports further translational investigation.